Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satoreotide Tetraxetan in SSTR2+ SCLC and Breast Cancer
NCT03773133Phase 2
Key facts
- Status
- Terminated
- Start
- May 2019
- Primary completion
- Oct 2019
- Countries
- 7
- Sponsor
- Ipsen
- Modality
- Peptide-Drug Conjugates
- Conditions
- small cell lung cancer (SCLC)breast cancer
01
Overview
Phase 2, open-label, single-arm trial of satoreotide tetraxetan in small cell lung cancer (SCLC) and breast cancer, sponsored by Ipsen. Primary endpoints: Maximum Tolerated Cumulative Activity and Objective Response Rate up to 90 days. Started May 2019; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment
Satoreotide tetraxetan i.v. administration.
03
Who it enrols
Adults with SSTR2-positive advanced Small Cell Lung Cancer or Breast Cancer who have progressed on standard of care.
04
Endpoints
Primary
Maximum Tolerated Cumulative Activity
Objective Response Rate
Beyond the preview
Go deeper on NCT03773133.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773133.